sEphB4-based gene therapy (Novartis/Genetic Therapy)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamesEphB4-based gene therapy (Novartis/Genetic Therapy)
Drug Alias NamesEphB4-based gene therapy (Genetic Therapy/Novartis)angiogenesis-inhibiting gene therapy (Genetic Therapy/Novartis)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionEphrin type-B receptor 4 modulators
TargetsEphrin type-B receptor 4
Therapy Area/IndicationsEye DiseasesArthritis, RheumatoidNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGenetic Therapy Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenetic Therapy Inc
Active IndicationsN/A
Inactive IndicationsEye DiseasesArthritis, RheumatoidNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A